EISAI CO., LTD. |
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
| 6.090 JPY | -0,03 % |
|
+1,30 % | -13,64 % |
| 12:00 | El escepticismo de los médicos frena la adopción de un fármaco contra el Alzheimer en EE.UU. | RE |
| 01/04 | Cogstate modifica el acuerdo de licencia con Eisai para el tratamiento del Alzheimer | MT |
Resumen de negocios
- productos farmacéuticos (87,7%): medicamentos prescritos, productos sanitarios, etc.;
- otros (12,3%): aditivos alimentarios, productos químicos, etc.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Japón (46,2%), Europa (19,5%), América (15,5%), China (10,3%) y otros (8,4%).
Número de empleados: 11 076
Ventas por actividad
| JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Pharmaceutical
91,9
%
| 626 281 | 82,8 % | 684 434 | 91,9 % | +9,29 % |
Other
8,1
%
| 129 945 | 17,2 % | 59 969 | 8,1 % | -53,85 % |
Ventas por región
| JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Japan
33,6
%
| 243 385 | 32,2 % | 250 327 | 33,6 % | +2,85 % |
Americas
32,1
%
| 226 719 | 30,0 % | 239 293 | 32,1 % | +5,55 % |
China
14,6
%
| 106 592 | 14,1 % | 108 562 | 14,6 % | +1,85 % |
Europe
11,6
%
| 126 745 | 16,8 % | 86 026 | 11,6 % | -32,13 % |
Other
8,1
%
| 52 784 | 7,0 % | 60 195 | 8,1 % | +14,04 % |
Directores
| Directores | Puesto | Edad | Desde |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/10/75 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yasushi Okada
COO | Chief Operating Officer | 65 | 01/04/81 |
Yosuke Akita
CMP | Compliance Officer | 59 | 01/04/89 |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01/04/88 |
Hideki Hayashi
BRD | Director/Board Member | 66 | 01/04/81 |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01/04/82 |
Masatomi Akana
IRC | Investor Relations Contact | 57 | 01/04/90 |
Sayoko Sasaki
IRO | Public Communications Contact | 55 | 01/04/91 |
Administradores
| Administradores | Puesto | Edad | Desde |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/10/75 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 01/06/21 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Hideki Hayashi
BRD | Director/Board Member | 66 | 01/04/81 |
Yuko Yasuda
BRD | Director/Board Member | 62 | - |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01/04/88 |
Hideyo Uchiyama
BRD | Director/Board Member | 71 | 01/06/18 |
Yumiko Miwa
BRD | Director/Board Member | 58 | 01/06/20 |
| Director/Board Member | 59 | 17/06/22 | |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01/04/82 |
Clase de acciones
| Vote | Quantity | Flotante | Autocontrol | Total Float | |
|---|---|---|---|---|---|
| Acción A | 0 | 296 566 949 | 278 292 124 ( 93,84 %) | 9 530 708 ( 3,214 %) | 93,84 % |
Participaciones
| Nombre | Acciones | % | Valoración |
|---|---|---|---|
EISAI CO., LTD. 3.21% | 9 530 200 | 3.21% | 391 421 706 $ |
MATSUKIYOCOCOKARA & CO. 1.97% | 8 445 000 | 1.97% | 136 123 266 $ |
| 474 000 | 0.96% | 11 071 327 $ | |
COGSTATE LIMITED 6.85% | 11 738 243 | 6.85% | 10 338 340 $ |
ROIVANT SCIENCES LTD. 0.11% | 874 957 | 0.11% | 9 222 047 $ |
VITAL KSK HOLDINGS, INC. 1.24% | 642 154 | 1.24% | 5 329 185 $ |
| 349 000 | 0.43% | 3 486 657 $ | |
| 546 000 | 2.24% | 3 138 659 $ | |
| 134 748 | 0.06% | 2 065 580 $ | |
| 56 608 | 0.14% | 184 024 $ |
Información de la empresa
Empresas del grupo
| Nombre | Categoría y sector |
|---|---|
Eisai Ltd. (United Kingdom)
 Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Eisai Ltd. (United Kingdom) is a pharmaceutical company based in Hatfield, UK. Part of Eisai Co., Ltd., Eisai Ltd. prioritizes patients and their families by continually improving the benefits that healthcare can provide. The British company was founded in 1988 and Gary Bryan Hendler has been the CEO of the company since 2008. |
Pharmaceuticals: Major
|
Eisai Pharmaceuticals India Pvt Ltd.
 Eisai Pharmaceuticals India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Pharmaceuticals India Pvt Ltd. is an Indian company that manufactures and exports drug substances. The private company is based in Visakhapatnam, India. The company was founded in 2007. The CEO is Sanjit Singh Lamba. |
Pharmaceuticals: Major
|
Eisai Manufacturing Ltd.
 Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The private company's official corporate website provides information on their initiatives and HHC concept. |
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Revisiones del BPA
| Varia. 1 de ene. | Capi. | |
|---|---|---|
| -13,64 % | 11,29 mil M | |
| +27,13 % | 659 mil M | |
| +27,68 % | 557 mil M | |
| -4,13 % | 359 mil M | |
| +16,53 % | 322 mil M | |
| +9,81 % | 297 mil M | |
| +6,30 % | 215 mil M | |
| +4,80 % | 210 mil M | |
| -6,05 % | 200 mil M | |
| -8,81 % | 149 mil M |
- Bolsa de valores
- Acciones
- Acción 4523
- Empresa Eisai Co., Ltd.
